SOUTHAMPTON, United Kingdom, Dec. 7, 2021 /PRNewswire/ -- Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral ...
NEW YORK CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) -- UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta The Chief Executive ...
Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. Of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback